C. Anderson

发表

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

K. Robison, A. Okamoto, L. Molinero, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

H. Ford, A. Thorburn, R. Camidge, 2013, Oncogene.

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

B. Monk, A. Tinker, A. Oza, 2021, The Lancet. Oncology.

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

K. Robison, L. Molinero, S. Pignata, 2020 .

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

B. Monk, Sileny N. Han, E. Braicu, 2022, Therapeutic advances in medical oncology.

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

B. Monk, M. Morgan, D. Provencher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

B. Monk, A. Tinker, A. Oza, 2019, Gynecologic Oncology.

Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39

A. Okamoto, L. Molinero, C. Landen, 2021, Gynecologic Oncology.

836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate

A. Tolcher, K. Papadopoulos, R. Mosher, 2020 .

738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial

D. O’Malley, A. Redondo, D. Lorusso, 2021, Annals of Oncology.

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

A. Tolcher, T. Burns, Melissa L. Johnson, 2020 .

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.

A. Stuckey, L. Molinero, S. Pignata, 2023, Gynecologic oncology.

Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial

A. Okamoto, L. Molinero, C. Landen, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.